In renal cell carcinoma (RCC), it was reported that high‐dose IL‐2 treatment in 20 patients elevated the plasma levels of CXCR3 ligands (CXCL9, CXCL10, and CXCL11), sequentially, forming an angiostatic environment 110. This evidence concerns the gene CXCL10 and renal cell carcinoma.